National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Zanamivir (Dectova®) which is indicated for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥6 months) when the patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.

 

NCPE Assessment Process Complete
Rapid review commissioned 26/08/2019
Rapid review completed 17/10/2019
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that zanamivir (Dectova®) be considered for reimbursement*.

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.